**Surgical Site Infection (SSI)**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Page 1 of 4 | | | | | | | | | | |
| \*required for saving \*\*required for completion | | | | | | | | | | |
| Facility ID: | | | | Event #: | | | | | | |
| \*Patient ID: | | | | Social Security #: | | | | | | |
| Secondary ID: | | | | Medicare #: | | | | | | |
| Patient Name, Last: | | | | First: | | | | | Middle: | |
| \*Gender: F M Other | | | | \*Date of Birth: | | | | | | |
| Ethnicity (Specify): | | | | Race (Specify): | | | | | | |
| \*Event Type: SSI | | | | \*Date of Event: | | | | | | |
| \*NHSN Procedure Code: | | | | ICD-10-PCS or CPT Procedure Code: | | | | | | |
| \*Date of Procedure: | | | | \*Outpatient Procedure: Yes No | | | | | | |
| \*MDRO Infection Surveillance: | | | | | | | | | | |
| □ Yes, this infection’s pathogen & location are in-plan for Infection Surveillance in the MDRO/CDI Module | | | | | | | | | | |
| □ No, this infection’s pathogen & location are **not** in-plan for Infection Surveillance in the MDRO/CDI Module | | | | | | | | | | |
| \*Date Admitted to Facility: | | | | | | Location: | | | | |
| **Event Details** | | | | | | | | | | |
| \*Specific Event: | | | | | | | | | | |
| □ Superficial Incisional Primary (SIP) | | | | | | | □ Deep Incisional Primary (DIP) | | | |
| □ Superficial Incisional Secondary (SIS) | | | | | | | □ Deep Incisional Secondary (DIS) | | | |
| □ Organ/Space (specify site): \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | | | | | | |  | | | |
| \*Infection present at the time of surgery (PATOS): □ Yes □ No | | | | | | | | | | |
| \*Specify Criteria Used (check all that apply): | | | | | | |  | | | |
| Signs & Symptoms | | | | | | | Laboratory | | | |
| □ Drainage or material† | | □ Sinus tract | | | | | □ Positive culture | | | |
| □ Pain or tenderness | | □ Hypothermia | | | | | □ Not cultured | | | |
| □ Swelling or inflammation | | □ Apnea | | | | | □ Positive blood culture(s) | | | |
| □ Erythema or redness | | □ Bradycardia | | | | | □ Positive culture from ≥ 2 separate tissue or fluid samples from affected joint | | | |
| □ Heat | | □ Lethargy | | | | |
| □ Fever | | □ Cough | | | | | □ Other positive laboratory tests† | | | |
| □ Incision deliberately opened/drained | | □ Nausea | | | | | □ Imaging test evidence of infection | | | |
| □ Wound spontaneously dehisces | | □ Vomiting | | | | |  | | | |
| □ Abscess | | □ Dysuria | | | | | Clinical Diagnosis | | | |
| □ Other evidence of infection found on invasive procedure, gross anatomic exam, or histopathologic exam † | | | | | | | □ Physician diagnosis of this event type | | | |
| □ Physician institutes appropriate antimicrobial therapy† | | | |
| □ Other signs & symptoms† | | | | | | |  | | | |
|  | | | | | | |  | | | |
| †per specific site criteria | | | | | | |  | | | |
| \*Detected: | □ A (During admission) | | □ P (Post-discharge surveillance) | | | | | | | |
| □ RF (Readmission to facility where procedure performed) | | | | | | | | | | |
| □ RO (Readmission to facility other than where procedure was performed) | | | | | | | | | | |
| \*Secondary Bloodstream Infection: Yes No | | | | | \*\*Died: Yes No | | | SSI Contributed to Death: Yes No | | |
| Discharge Date: | | | | | \*Pathogens Identified: Yes No | | | | | \*If Yes, specify on pages 2-3. |
| Assurance of Confidentiality: The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)).  Public reporting burden of this collection of information is estimated to average 35 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC, Reports Clearance Officer, 1600 Clifton Rd., MS D-74, Atlanta, GA 30333, ATTN: PRA (0920-0666).  CDC 57.120 (Front) Rev 6, v8.3 | | | | | | | | | | |

**Surgical Site Infection (SSI)**

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Page 2 of 4 | | | | | | | | | | | | |
| Pathogen # | **Gram-positive Organisms** | | | | | | | | | | | |
| \_\_\_\_\_\_\_ | *Staphylococcus* coagulase-negative | | | **VANC**  S I R N | | | | | | | | |
| (specify species if available):  \_\_\_\_\_\_\_\_\_\_\_\_ | | | | | | | | | | | |
| \_\_\_\_\_\_\_ | *\_\_\_\_Enterococcus faecium*  *\_\_\_\_Enterococcus faecalis*    *\_\_\_\_Enterococcus* spp.  (Only those not identified to the species level) | | | **DAPTO**  S NS N | **GENTHL§**  S R N | | **LNZ**  S I R N | | **VANC**  S I R N | |  | |
| \_\_\_\_\_\_\_ | *Staphylococcus aureus* | **CIPRO/LEVO/MOXI**  S I R N | | **CLIND**  S I R N | **DAPTO**  S NS N | **DOXY/MINO**  S I R N | | | **ERYTH**  S I R N | | **GENT**  S I R N | **LNZ**  S R N |
| **OX/CEFOX/METH**  S I R N | | **RIF**  S I R N | **TETRA**  S I R N | **TIG**  S NS N | | | **TMZ**  S I R N | | **VANC**  S I R N |  |
| Pathogen # | **Gram-negative Organisms** | | | | | | | | | | | |
| \_\_\_\_\_\_\_ | *Acinetobacter*  (specify species)  \_\_\_\_\_\_\_\_\_\_\_\_ | **AMK**  S I R N | **AMPSUL**  S I R N | **AZT**  S I R N | **CEFEP**  S I R N | **CEFTAZ**  S I R N | | | **CIPRO/LEVO**  S I R N | | | **COL/PB**  S I R N |
| **GENT**  S I R N | **IMI**  S I R N | **MERO/DORI**  S I R N | | **PIP/PIPTAZ**  S I R N | | | | | **TETRA/DOXY/MINO**  S I R N | |
| **TMZ**  S I R N | **TOBRA**  S I R N |  | | | | | | | | |
| \_\_\_\_\_\_\_ | *Escherichia coli* | **AMK**  S I R N | **AMP**  S I R N | **AMPSUL/AMXCLV**  S I R N | | **AZT**  S I R N | | **CEFAZ**  S I R N | | **CEFEP**  S I/S-DD R N | | **CEFOT/CEFTRX**  S I R N |
| **CEFTAZ**  S I R N | **CEFUR**  S I R N | **CEFOX/CTET**  S I R N | | **CIPRO/LEVO/MOXI**  S I R N | | | | **COL/PB†**  S R N | | |
| **ERTA**  S I R N | **GENT**  S I R N | **IMI**  S I R N | **MERO/DORI**  S I R N | | | **PIPTAZ**  S I R N | | **TETRA/DOXY/MINO**  S I R N | | |
| **TIG**  S I R N | **TMZ**  S I R N | **TOBRA**  S I R N |  | | | | | | | |
| \_\_\_\_\_\_\_ | *Enterobacter*  (specify species)  \_\_\_\_\_\_\_\_\_\_\_\_ | **AMK**  S I R N | **AMP**  S I R N | **AMPSUL/AMXCLV**  S I R N | | **AZT**  S I R N | | **CEFAZ**  S I R N | | **CEFEP**  S I/S-DD R N | | **CEFOT/CEFTRX**  S I R N |
| **CEFTAZ**  S I R N | **CEFUR**  S I R N | **CEFOX/CTET**  S I R N | | **CIPRO/LEVO/MOXI**  S I R N | | | | **COL/PB†**  S R N | | |
| **ERTA**  S I R N | **GENT**  S I R N | **IMI**  S I R N | **MERO/DORI**  S I R N | | | **PIPTAZ**  S I R N | | **TETRA/DOXY/MINO**  S I R N | | |
| **TIG**  S I R N | **TMZ**  S I R N | **TOBRA**  S I R N |  | | | | | | | |
| \_\_\_\_\_\_\_ | *\_\_\_\_Klebsiella*  *pneumonia*  *\_\_\_\_Klebsiella*  *oxytoca* | **AMK**  S I R N | **AMP**  S I R N | **AMPSUL/AMXCLV**  S I R N | | **AZT**  S I R N | | **CEFAZ**  S I R N | | **CEFEP**  S I/S-DD R N | | **CEFOT/CEFTRX**  S I R N |
| **CEFTAZ**  S I R N | **CEFUR**  S I R N | **CEFOX/CTET**  S I R N | | **CIPRO/LEVO/MOXI**  S I R N | | | | **COL/PB†**  S R N | | |
| **ERTA**  S I R N | **GENT**  S I R N | **IMI**  S I R N | **MERO/DORI**  S I R N | | | **PIPTAZ**  S I R N | | **TETRA/DOXY/MINO**  S I R N | | |
| **TIG**  S I R N | **TMZ**  S I R N | **TOBRA**  S I R N |  | | | | | | | |

**Surgical Site Infection (SSI)**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Page 3 of 4 | | | | | | | | | | | | | | | | | | |
| Pathogen # | **Gram-negative Organisms (*continued*)** | | | | | | | | | | | | | | | | | |
| \_\_\_\_\_\_\_ | *Pseudomonas aeruginosa* | **AMK**  S I R N | | | **AZT**  S I R N | **CEFEP**  S I R N | | **CEFTAZ**  S I R N | | | | **CIPRO/LEVO**  S I R N | | | **COL/PB**  S I R N | | **GENT**  S I R N | |
| **IMI**  S I R N | | | **MERO/DORI**  S I R N | | | **PIP/PIPTAZ**  S I R N | | | | **TOBRA**  S I R N | | | | | | |
| Pathogen # | **Fungal Organisms** | | | | | | | | | | | | | | | | | |
| \_\_\_\_\_\_\_ | *Candida*  (specify species if available)  \_\_\_\_\_\_\_\_\_\_\_\_ | **ANID**  S I R N | **CASPO**  S NS N | | | **FLUCO**  S S-DD R N | | | | **FLUCY**  S I R N | | **ITRA**  S S-DD R N | | | **MICA**  S NS N | | **VORI**  S S-DD R N | |
| Pathogen # | **Other Organisms** | | | | | | | | | | | | | | | | | |
| \_\_\_\_\_\_\_ | Organism 1 (specify)  \_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_Drug 1  S I R N | | \_\_\_\_\_\_\_ Drug 2  S I R N | | | \_\_\_\_\_\_  Drug 3  S I R N | | \_\_\_\_\_\_\_ Drug 4  S I R N | | \_\_\_\_\_\_\_Drug 5  S I R N | | \_\_\_\_\_\_ Drug 6  S I R N | \_\_\_\_\_\_ Drug 7  S I R N | | \_\_\_\_\_\_ Drug 8  S I R N | | \_\_\_\_\_\_ Drug 9  S I R N |
| \_\_\_\_\_\_\_ | Organism 1 (specify)  \_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_Drug 1  S I R N | | \_\_\_\_\_\_\_ Drug 2  S I R N | | | \_\_\_\_\_\_  Drug 3  S I R N | | \_\_\_\_\_\_\_ Drug 4  S I R N | | \_\_\_\_\_\_\_Drug 5  S I R N | | \_\_\_\_\_\_ Drug 6  S I R N | \_\_\_\_\_\_ Drug 7  S I R N | | \_\_\_\_\_\_ Drug 8  S I R N | | \_\_\_\_\_\_ Drug 9  S I R N |
| \_\_\_\_\_\_\_ | Organism 1 (specify)  \_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_Drug 1  S I R N | | \_\_\_\_\_\_\_ Drug 2  S I R N | | | \_\_\_\_\_\_  Drug 3  S I R N | | \_\_\_\_\_\_\_ Drug 4  S I R N | | \_\_\_\_\_\_\_Drug 5  S I R N | | \_\_\_\_\_\_ Drug 6  S I R N | \_\_\_\_\_\_ Drug 7  S I R N | | \_\_\_\_\_\_ Drug 8  S I R N | | \_\_\_\_\_\_ Drug 9  S I R N |

**Result Codes**

**S = Susceptible I = Intermediate R = Resistant NS = Non-susceptible S-DD = Susceptible-dose dependent N = Not tested**

**§ GENTHL results: S = Susceptible/Synergistic and R = Resistant/Not Synergistic**

**† Clinical breakpoints have not been set by FDA or CLSI, Sensitive and Resistant designations should be based upon epidemiological cutoffs of Sensitive MIC ≤ 2 and Resistant MIC ≥ 4**

|  |  |  |  |
| --- | --- | --- | --- |
| **Drug Codes:** |  |  |  |
| AMK = amikacin | CEFTRX = ceftriaxone | FLUCY = flucytosine | OX = oxacillin |
| AMP = ampicillin | CEFUR= cefuroxime | GENT = gentamicin | PB = polymyxin B |
| AMPSUL = ampicillin/sulbactam | CTET= cefotetan | GENTHL = gentamicin –high level test | PIP = piperacillin |
| AMXCLV = amoxicillin/clavulanic acid | CIPRO = ciprofloxacin | IMI = imipenem | PIPTAZ = piperacillin/tazobactam |
| ANID = anidulafungin | CLIND = clindamycin | ITRA = itraconazole | RIF = rifampin |
| AZT = aztreonam | COL = colistin | LEVO = levofloxacin | TETRA = tetracycline |
| CASPO = caspofungin | DAPTO = daptomycin | LNZ = linezolid | TIG = tigecycline |
| CEFAZ= cefazolin | DORI = doripenem | MERO = meropenem | TMZ = trimethoprim/sulfamethoxazole |
| CEFEP = cefepime | DOXY = doxycycline | METH = methicillin | TOBRA = tobramycin |
| CEFOT = cefotaxime | ERTA = ertapenem | MICA = micafungin | VANC = vancomycin |
| CEFOX= cefoxitin | ERYTH = erythromycin | MINO = minocycline | VORI = voriconazole |
| CEFTAZ = ceftazidime | FLUCO = fluconazole | MOXI = moxifloxacin |  |

**Surgical Site Infection (SSI)**

|  |  |  |  |
| --- | --- | --- | --- |
| Page 4 of 4 | | | |
| **Custom Fields** | | | |
| Label | | Label | |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_/\_\_\_\_/\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_/\_\_\_\_/\_\_\_\_\_ |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | \_\_\_\_\_\_\_\_\_\_\_\_\_\_ |
| **Comments** | | | |
|  | | | |